CML Treated With Bosutinib After Relapse

• Status: Completed
• Trial end date: 2019-06-27

Summary

Prospective, open label, multicenter, phase II study evaluating correlation of SNPs with efficacy and toxicity in patients treated with Bosutinib. A total of 50 patients with previously treated Ph+ chronic phase CML will be included in the study

• Phase: Phase 2

Details

• Lead Sponsor: PETHEMA Foundation